EUVIMEDEUVIMED entdecken
Open Access

Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno‐Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction

Yuji Shi, Patricia Perez-Bonilla, Xian Chen iD, Kelly Tam, Mackenzie Marshall, Jeffrey Morin iD, Brianna LaViolette iD, Nouaying R Kue, Federico Damilano, Russell A Miller iD, Bei B Zhang, Rachel J Roth Flach iD und 1 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.035894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Yuji Shi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Research Unit Cambridge MA. Hauptthemen laut MEDLINE: Disease Models, Animal, Heart Failure, Renin, Stroke Volume. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure with preserved ejection fraction (HFpEF) currently accounts for more than half of patients with HF, with limited approved evidence‐based therapies. HFpEF is a complex multifactorial disease associated with hypertension, obesity, diabetes, and renal dysfunction. In addition to our limited understanding of HFpEF pathophysiology, the development of new therapies is partially hindered by the existing translationally relevant preclinical HFpEF models. Methods and Results Here, we report the development of a novel 2‐hit HFpEF male mouse model through adding hypertensive stress from the activation of the renin‐angiotensin‐aldosterone system with adeno‐associated viral‐renin (AAV‐renin), to the metabolic syndrome nonalcoholic steatohepatitis (MSNASH, formerly FATZO) mouse (MSNASH+AAV‐renin). To further demonstrate model translatability, MSNASH+AAV‐renin mice were then treated with approved HFpEF therapies sacubitril/valsartan or a combination of sacubitril/valsartan and empagliflozin. We found that the MSNASH+AAV‐renin mouse model demonstrates clinically relevant features of human HFpEF, including preserved ejection fraction, cardiac hypertrophy, left atrial enlargement, diastolic dysfunction, elevated natriuretic peptides, inflammation, and low exercise capacity. We also demonstrate that treatment with approved HFpEF therapies sacubitril/valsartan and the combination of sacubitril/valsartan with empagliflozin improves the cardiac phenotypes of HFpEF in this model.

Conclusions

The MSNASH+AAV‐renin model faithfully represents a severe cardiometabolic HFpEF phenogroup that can be used as a new tool for HFpEF preclinical research and drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease Models, AnimalHeart FailureReninStroke VolumeValsartanDependovirusRenin-Angiotensin SystemNon-alcoholic Fatty Liver DiseaseMetabolic SyndromeAnimalsMaleMiceAminobutyratesDrug CombinationsBiphenyl CompoundsVentricular Function, LeftTetrazolesMice, Inbred C57BLBenzhydryl CompoundsGenetic VectorsAngiotensin Receptor Antagonists

Stichwörter der Autor:innen

HFpEFMSNASHcardiometabolismempagliflozinmouse modelsreninsacubitril/valsartan

Substanzen

ReninValsartanAminobutyratessacubitril and valsartan sodium hydrate drug combinationDrug CombinationsBiphenyl CompoundsTetrazolesBenzhydryl CompoundsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Internal Medicine Research Unit Cambridge MA.
  • Pfizer Inc. Cambridge MA.
  • Global Discovery, Investigative & Translational Sciences - Animal Models & Imaging Cambridge MA.

ORCID-Profile: Xian Chen, Jeffrey Morin, Brianna LaViolette, Russell A Miller, Rachel J Roth Flach, Dinesh Hirenallur-Shanthappa

Zitieren

APA

Shi, Y., Perez-Bonilla, P., Chen, X., Tam, K., Marshall, M., Morin, J., LaViolette, B., Kue, N. R., Damilano, F., Miller, R. A., Zhang, B. B., Roth Flach, R. J., & Hirenallur-Shanthappa, D. (2024). Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno‐Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.035894

Vancouver

Shi Y, Perez-Bonilla P, Chen X, Tam K, Marshall M, Morin J, et al. Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno‐Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.035894

BibTeX
@article{Shi2024,
  author = {Shi, Yuji and Perez-Bonilla, Patricia and Chen, Xian and Tam, Kelly and Marshall, Mackenzie and Morin, Jeffrey and LaViolette, Brianna and Kue, Nouaying R and Damilano, Federico and Miller, Russell A and Zhang, Bei B and Roth Flach, Rachel J and Hirenallur-Shanthappa, Dinesh},
  title = {Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno‐Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.035894}
}
Kostenlos starten →